LIST OF ADULT CANCER COOPERATIVE GROUPS AND BREAST CANCER CLINICAL TRIALS Web link

AMERICAN COLLEGE OF RADIOLOGY IMAGING NETWORK (ACRIN) Web link

The primary goal of the American College of Radiology Imaging Network (ACRIN) is to generate information through clinical trials of diagnostic imaging and image-guided therapeutic technologies that will lengthen and improve the quality of the lives of cancer patients. ACRIN is currently funded by the NCI for five years (1999 -2004). Unlike other cooperative groups, ACRIN has no permanent members. Rather, institutions become qualified to participate in trials conducted by ACRIN’s Institutional Participants Committee.

Open Breast Cancer Protocols

ACRIN-6652
Screening and Diagnostic Study of Digital Mammography Versus Screen-Film
Mammography in the Detection of Breast Cancer in Women Protocol

Contact Information
ACRIN Network Chair: Dr Bruce Hillman
Phone:(804) 982-0211, E-mail:bjh8a@virginia.edu

ACRIN Administrator:Irene Mahon
Phone:(215) 574-3231,E-mail:IMAHON@phila.acr.org

AMERICAN COLLEGE OF SURGEONS ONCOLOGY (ACOSOG) Web link

The American College of Surgeons Oncology Group (ACOsSOG) is a multidisciplinary cooperative group that focuses on evaluating diagnostic and therapeutic procedures in patients with the most common malignant solid tumors including breast, lung and colorectal cancers. Membership includes general and specialty surgeons, medical oncologists, gynecologists, radiologists, radiation therapists, geneticists, basic laboratory investigators and allied health professionals in the private community as well as at academic centers.

Open Breast Cancer Protocols

ACOSOG-Z0010;GUMC-00152
Phase III Prognostic Study of Sentinel Node and Bone Marrow Micrometastases in Women with Stage I or IIA Breast Cancer Protocol

ACOSOG-Z0011;GUMC-00153
Phase III Randomized Study of Axillary Lymph Node Dissection in Women with Stage I or IIA Breast Cancer Who Have a Positive Sentinel Node Protocol

Contact Information
American College of Surgeons Oncology Group
Box 3627
Duke University Medical Center
Durham, NC 27710
Phone:(919) 668-8549, Fax:(919) 668-7122

Group Chair: Samuel A Wells, Jr, MD, FACS
Phone:(919) 668-8435, E-mail:wells029@surgerytrials.duke.edu
Group Administrator:Mary Ruemker
Phone:(919) 668-8018, E-mail:ruemk001@surgerytrials.duke.edu

CANCER AND LEUKEMIA GROUP B (CALGB) Web link

The Cancer and Leukemia Group B (CALGB) is a national clinical research group that conducts clinical trials in patients with leukemia, lymphoma, melanoma, breast cancer, lung cancer, genitourinary malignancies, gastrointestinal malignancies and prostate cancer. CALGB’s studies aim to reduce the morbidity and mortality from cancer, relate the biological characteristics of cancer to clinical outcomes and develop new strategies for the early detection and prevention of cancer. CALGB is headquartered at the University of Chicago, and its statistical center is located at Duke University. Founded in 1955, CALGB has grown into a network of 29 university medical centers, over 185 community hospitals and more than 3,000 physicians.

Open Breast Cancer Protocols

CLB-9871
Phase II Study of Docetaxel in Caucasian and African American Patients with Solid Tumors Protocol

CLB-49808; CTSU
Phase III Randomized Study of Doxorubicin and Cyclophosphamide with or without Dexrazoxane, Followed by Paclitaxel with or without Trastuzumab (Herceptin), Followed by Surgery and Radiotherapy with or without Trastuzumab in Women with HER2+ Stage IIIA or IIIB or Regional Stage IV Breast Cancer Protocol

CAN-NCIC-MA17; CLB-49805; EORTC-10983; JRF-Vor-Int-10; NCCTG-CAN-MA17; SWOG-CAN-MA17
Phase III Randomized Study of Letrozole Versus Placebo in Women with Primary Breast Cancer Who Have Completed at Least Five Years of Adjuvant Tamoxifen Protocol

CLB-9840; CTSU
Phase III Randomized Study of Paclitaxel Via One-Hour Infusion Every Week Versus Three-Hour Infusion Every 3 Weeks with or without Trastuzumab (Herceptin) in Patients with Inoperable, Recurrent or Metastatic Breast Cancer with or without Overexpression of HER2-Neu Protocol

CLB-79809; NCI-P01-0184
Phase III Randomized Study of Zoledronate,Calcium and Cholecalciferol (Vitamin D)to Prevent Bone Loss in Women with Breast Cancer Receiving Adjuvant Chemotherapy Protocol

Contact Information
CALGB Central Office
208 South LaSalle Street, Suite 2000
Chicago, IL 60604
Phone:(773) 702-9171, Fax:(312) 345-0117

Page 3 of 6
Previous Page | Next page

Home · Search